Alnylam Pharma (ALNY) Tops Q1 EPS by 35c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/23/2026

1. META
2. TSLA
3. IBM
4. TXN
5. SAP
6. MRNA
7. CSX
8. SPCX
9. WDC
10. MRK

Go back to Alnylam Pharma (ALNY) Tops Q1 EPS by 35c

Alnylam Pharmaceuticals Reports First Quarter 2022 Financial Results and Highlights Recent Period Activity

April 28, 2022 8:00 AM EDT

Achieved First Quarter 2022 Global Net Product Revenues of $187 Million for ONPATTRO®, GIVLAARI®, and OXLUMO®

Reported Positive 18-Month Results from HELIOS-A Phase 3 Study of Vutrisiran in hATTR Amyloidosis Patients with Polyneuropathy

Announced 3-Month Extension of Review Period for New Drug Application for Vutrisiran due to Amendment to Address Pending Inspection Classification at Third-Party Secondary Packaging and Labeling Facility

Decreased 2022 Guidance Range for Combined Net Product Revenues from $900 Million $1 Billion to $870 $930 Million

CAMBRIDGE, Mass.--(BUSINESS WIRE)--

... More